


## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1479076/publications.pdf Version: 2024-02-01



×7.	CAO	
Y A	1.10	

#	Article	IF	CITATIONS
1	Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors. EBioMedicine, 2020, 56, 102796.	6.1	7
2	TMOD-25. MODELING IDH1-MUTATED GLIOMAS: GENERATION, CHARACTERIZATION AND THERAPEUTIC SENSITIVITIES OF SEVEN PATIENT-DERIVED IDH1-MUTANT GLIOMA CELL LINES. Neuro-Oncology, 2018, 20, vi274-vi274.	1.2	0
3	Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas. Cancers, 2018, 10, 489.	3.7	18
4	DRES-14. PROTEIN AGGREGATE FORMATION PREDICTS CLINICAL RESPONSES TO EGFR TKIs. Neuro-Oncology, 2018, 20, vi78-vi78.	1.2	0
5	IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis. PLoS ONE, 2018, 13, e0199737.	2.5	4
6	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. Cancer Research, 2016, 76, 525-534.	0.9	93
7	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathologica Communications, 2015, 3, 88.	5.2	42
8	Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro-Oncology, 2015, 17, 935-941.	1.2	136
9	Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation. European Journal of Cancer, 2015, 51, 893-903.	2.8	21